Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes
Document Type
Article
Publication Date
3-1-2026
Abstract
Background Current guidelines recommend a two-step approach for risk stratification of metabolic dysfunction-associated steatotic liver disease (MASLD), starting with Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE). Objective To evaluate this approach for predicting advanced fibrosis and liver-related events (LREs) in patients with type 2 diabetes (T2D). Design A prospective liver biopsy cohort of T2D patients with histologically confirmed MASLD from seven centres in China was used to assess diagnostic performance for advanced fibrosis. The international VCTE-Prognosis cohort, including T2D patients with MASLD who underwent VCTE at 16 centres in the USA, Europe and Asia, with longitudinal follow-up, was used to assess LREs, defined as hepatic decompensation or hepatocellular carcinoma. Results 4781 participants were included. In the liver biopsy cohort (n=352; 22.2% with advanced fibrosis), applying LSM thresholds of < 8 kPa and >12 kPa after FIB-4 classified patients into 63.4% low-risk, 9.4% intermediate-risk and 27.3% high-risk, with a correct classification rate of 71%. In the VCTE-Prognosis cohort (n=4429; median follow-up 51.3 (IQR 27.4-70.7) months), 140 (3.2%) patients developed LREs (110 (2.5%) with hepatic decompensation and 59 (1.3%) with hepatocellular carcinoma). The two-step approach classified 72.6%, 6.8% and 20.6% of patients into low-risk, intermediate-risk and high-risk groups, with corresponding 5-year cumulative LRE incidences of 0.7%, 0.9% and 11.8%. Refining classification of intermediate FIB-4 patients using LSM < 10 kPa (low-risk) and >15 kPa (high-risk) reduced the intermediate-risk group to 5.6% while preserving predictive accuracy. Conclusion The non-invasive two-step approach of FIB-4 followed by LSM effectively stratifies MASLD-related advanced fibrosis and LREs risk in T2D. Applying LSM cut-offs of 10 and 15 kPa further optimises risk stratification for future LREs.
Keywords
DIABETES MELLITUS, TYPE 2, FATTY LIVER, HEPATIC FIBROSIS
Publication Title
Gut
ISSN
0017-5749
DOI
10.1136/gutjnl-2025-337506
Recommended Citation
Chen, Yuping; Dong, Bingtian; Jin, Xinrui; Liu, Chuan; Zheng, Ming Hua; Liang, Xiao; Sun, Yameng; Lee, Hye Won; Lin, Huapeng; Tsochatzis, Emmanuel; Petta, Salvatore; Bugianesi, Elisabetta; Yoneda, Masato; Hagström, Hannes; Boursier, Jérôme; Calleja, José Luis; Goh, George Boon Bee; and Chan, Wah Kheong, "Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" (2026). Research Publications (2026 to 2030). 1217.
https://knova.um.edu.my/research_publications_2026_2030/1217
Funders
Chinese University of Hong Kong (B53C22006110001, 2024.065, PNC0000001), General Research Fund of the Hong Kong (14106923), Southeast University (2023YJXYYRCPY03, CZXM-GSP-RC119, CZXM-GSP-RC125, 3290002303A2, NCIM25-4, ZDYYGSPLCYJ02), Key Research and Development Program of Jiangsu Province (BE2023767), National Natural Science Foundation of China (82402413), Natural Science Foundation of Jiangsu Province (BK20241681), Health Research Program of Anhui (AHWJ2023A30169), Natural Science Foundation of Anhui Province (2023ZD0508700, 2508085QH314), Anhui Provincial Department of Education ( 2025AHGXZK40632), China Postdoctoral Science Foundation (2024M750461)
Volume
75
Issue
3
First Page
576
Last Page
587
Publisher
BMJ Publishing Group